ConductScience.org, home

Paper6283384

T24 human bladder carcinoma oncogene is an activated form of the normal human homologue of BALB- and Harvey-MSV transforming genes.

Santos E and 4 others. Nature, 1982. Cited by 592 papers, by iCite.

Cite this record

ConductScience Library. T24 human bladder carcinoma oncogene is an activated form of the normal human homologue of BALB- and Harvey-MSV transforming genes. Papers, record 6283384. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/6283384

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
T24 human bladder carcinoma oncogene is an activated form of the normal human homologue of BALB- and Harvey-MSV transforming genes.
PubMed
Journal
Nature
PubMed
Year
1982
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
592
iCite
Relative citation ratio, by iCite
9.55
iCite
Revised in PubMed
2019-06-17
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Santos EE
2Tronick SRS R
3Aaronson SAS A
4Pulciani SS
5Barbacid MM

Source PubMed

Download CSV of authors

Topics17

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
CarcinomaMajor topic
Sarcoma Viruses, MurineMajor topic
Urinary Bladder NeoplasmsMajor topic
Animals
Antibodies, Neoplasm
Base Sequence
Cell Line
DNA
DNA Restriction Enzymes
Genes, Viral
Humans
Mice
Mice, Inbred BALB C
Neoplasms, Experimental
Nucleic Acid Hybridization
Phosphoproteins
Viral Proteins

Source PubMed

Download CSV of topics

Cited by195

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 592 citations.

PMIDTitleJournalYearIn PapersSource
42282028Modulation of Oncogenic KRAS Signaling by Branched Actin-driven Cell Membrane Protrusions.Res Sq2026https://conductscience.org/library/papers/42282028PubMed
42039391Modulation of Oncogenic KRAS Signaling by Branched Actin-driven Cell Membrane Protrusions.bioRxiv2026https://conductscience.org/library/papers/42039391PubMed
42032343Epithelial-to-mesenchymal transition as a central driver of tumor cell plasticity.Nat Cancer2026https://conductscience.org/library/papers/42032343PubMed
42022579Disrupting the KRAS-SOS1 protein-protein interaction: mechanistic rationale for pan-KRAS pathway suppression and combination therapy.Front Chem2026https://conductscience.org/library/papers/42022579PubMed
41882629SOS1: tracking the evolving path from promising to actionable therapeutic target in RAS-dependent cancers.Mol Cancer2026https://conductscience.org/library/papers/41882629PubMed
41323424KRAS-targeted therapies in cancer: novel approaches and overcoming resistance.BMJ Oncol2025https://conductscience.org/library/papers/41323424PubMed
41309533Targeting KRAS mutations: orchestrating cancer evolution and therapeutic challenges.Signal Transduct Target Ther2025https://conductscience.org/library/papers/41309533PubMed
40953126Horizontally transferred cell-free chromatin particles function as autonomous 'satellite genomes' and vehicles for transposable elements within host cells.Elife2025https://conductscience.org/library/papers/40953126PubMed
40906088RESEARCH CHALLENGES IN STAGE III AND IV RAS-ASSOCIATED CANCERS: A Narrative Review of the Complexities and Functions of the Family of RAS Genes and Ras Proteins in Housekeeping and Tumorigenesis.Biology (Basel)2025https://conductscience.org/library/papers/40906088PubMed
40664734Induction of cancer stem cells from mouse fibroblasts.Sci Rep2025https://conductscience.org/library/papers/40664734PubMed
39638567"Undruggable KRAS": druggable after all.Genes Dev2025https://conductscience.org/library/papers/39638567PubMed
39456601Tolerance of Oncogene-Induced Replication Stress: A Fuel for Genomic Instability.Cancers (Basel)2024https://conductscience.org/library/papers/39456601PubMed
39455281Molecular and cellular dynamics of squamous cell carcinomas across tissues.Genes Dev2025https://conductscience.org/library/papers/39455281PubMed
38890350Tumor initiation and early tumorigenesis: molecular mechanisms and interventional targets.Signal Transduct Target Ther2024https://conductscience.org/library/papers/38890350PubMed
38463630Interactions between Ras and Rap signaling pathways during neurodevelopment in health and disease.Front Mol Neurosci2024https://conductscience.org/library/papers/38463630PubMed
36494601Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors.NPJ Precis Oncol2022https://conductscience.org/library/papers/36494601PubMed
35244677Understanding and drugging RAS: 40 years to break the tip of the iceberg.Dis Model Mech2022https://conductscience.org/library/papers/35244677PubMed
35234863RAS pathway regulation in melanoma.Dis Model Mech2022https://conductscience.org/library/papers/35234863PubMed
35045886The path to the clinic: a comprehensive review on direct KRASG12C inhibitors.J Exp Clin Cancer Res2022https://conductscience.org/library/papers/35045886PubMed
34439794Anthraquinones as Inhibitors of SOS RAS-GEF Activity.Biomolecules2021https://conductscience.org/library/papers/34439794PubMed

See all 195 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/6283384

GET https://conductscience.org/api/papers/v1/6283384/cited_by?page=2